Infection with hepatitis C virus as a cause of cirrhosis – case study
DOI:
https://doi.org/10.12775/JEHS.2025.77.58188Keywords
HCV infection, hepatitis C complications, liver cirrhosisAbstract
Background and study aims. HCV may cause an acute or chronic hepatitis C and, when left untreated, may lead to cirrhosis and/or primary liver cancer. The aim of the study was analysis of personal medical records of a patient with cirrhosis from the aspect of its relation with HCV infection;
Materials and Method. A case of a 36-year old patient was presented diagnosed with cirrhosis, admitted to the emergency department due to haemorrhage from the upper gastrointestinal tract. Anti-HCV antibodies were present. The method was a case study, the technique – analysis of records the research tool – case history with the results of diagnostic tests, visual analogue scale (VAS) measuring pain intensity, the Hamilton Depression Rating Scale, fluid balance chart, and an author-constructed questionnaire to be completed by the patient;
Results. Based on internal documentation of the hospital and patient medical records a case of a patient was described with gastrointestinal bleeding and cirrhosis, diagnosed with HCV. Physical examination was presented, as well as epidemiological interview, medical history, course of diagnostics and treatment of the patient qualified for follow up ambulatory care in the outpatient hepatology department.
Conclusions. Screening tests are recommended in order to early diagnose the presence of anti-HCV antibodies. Early diagnosis of infection with HCV and implementation of anti-viral treatment may prevent cirrhosis of the liver. Health education of society is necessary from the aspect of risk factors of HCV infection in the medical environment, as well as in beauty salons and tattoo parlours.
References
1.SALLAM M, KHAIL R. Contemporary insights into hepatitis C virus: a comprehensive review. Microorganisms, 2024, 12: 1035.
2.STASI C, MILLI C, VOLLER F, SILVESTRI C. The epidemiology of chronic hepatitis C: where we are now. Livers, 2024, 4: 172-181.
3.CHOO QL, KUO G, WEINER AJ, OVERBY LR, BRADLEY DW. Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 1989, 244: 359-362.
4.TOK D. Analysis of articles on hepatitis C by scientific mapping: 1989-2022. World J Clin Cases, 2024, 12: 4301-4316.
5.ECHEVERRIA N, COMAS V, ALDUNATE F, PERBOLIANACHIS P, MORENO P, CRISTINA J. In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet? Word J Hepatol, 2021, 13: 1234-1268.
6.HALEY RW, FISCHER RP. Commercial tattooing as a potentially important source of hepatitis C infection: Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine, 2021, 80: 134-151.
7.SHAYEGHPOUR A, KIANFAR R, HOSSEINI P, AJORLOO M. AGHAJANIN S. YAGHOOBI MH, et al. Hepatitis C virus DNA vaccines: A systematic review. Virol. J, 2021, 18: 248.
8.ZHAO Q, HE K, ZHANG X, XU M. ZHANG X, LI H. Production and immunogenicity of different prophylactic vaccines for hepatitis C virus (Review). Exp. Ther. Med, 2022, 24: 474.
9.GOMEZ-ESCOBAR E, ROINGEARD P, BEAUMONT E. Current hepatitis C vaccine candidates based on the induction of neutralizing antibodies. Viruses, 2023, 15: 1151.
10.VO-QUANG E, PAWLOTSKY JM. Unusual’ HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment. BMJ Journal Gut, 2024, 73: 1570-1582.
11.FLISIAK R, POGORZELSKA J, BERAK H, HORBAN H, ORŁOWSKA I, SIMON K, et al. Prevalence of HCV genotypes in Poland-The EpiTer study. Clin. Exp. Hepat, 2016, 2: 144-148.
12.HALOTA W, FLISIAK R, JUSZCZYK J, MALKOWSKI P, PAWŁOWSKA M, SIMON K, et al. Recommendations for the treatment of viral hepatitis C in 2019 by Polish Group of Experts for HCV. Hepat, 2019, 19: 1-9.
13.IMBETH-ACOSTA P, LEAL-MARTINEZ V, RAMOS-CLASON E, PAJARO-GALVIS N, MARTINEZ-AVILA MC, ALMANZA-HURTADO, et al. Prevalence of Chronic Infection by Hepatitis C Virus in Asymptomatic Population With Risk Factors in Cartagena, Colombia. Front Med, 2022, 9: 814622.
14.EASL recommendations on treatment of hepatitis C: Final update of the series. Journal of Hepatology, 2020, 73: 11701218.
15.MARTINELLO M, SOLOMON SS, TERRAULT NA, DOTE GJ. Hepatitis C. Lancet, 2023, 402: 1085-1096.
16.KIM DJ. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. J Liver Cancer, 2024, 24: 62-70.
17.LLOVET JM, KELLEY RK, VILLANUEVA A, SINGAL AG, PIKARSKY E, ROAYAIE S, et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers, 2021, 7: 6.
18.MITHU M, APARNA S, PRANJAL S, JYOTI NB, CHIMANJITA P. Socio-demographic association with confirmed hepatitis C virus infection: A cross-sectional analysis from a teaching institute. J Fam Med Prim Care, 2024, 13: 2060-2065.
19.MENDIZABAL M, CANCADO GGL, ALBILLOS A. Evolving portal hypertension through Baveno VII recommendations. Ann Hepatol, 2024, 29: 101180.
20. STOENESCU AF, POPESCU CP, FLORESCU SA, VANCEA G, CEAUSU E, CALISTRU P. The prevalence of depression and its potential link to liver fibrosis in patients diagnosed with chronic hepatitis C virus infection prior to the initiation of direct-acting antiviral treatment. Cureus, 2024, 16: e62970.
21. GIŃES P, ABRALDES JG, SOLA E, FABRELLAS N, KAMATH PS. Liver cirrhosis. Lancet, 2021, 398: 9-15.
22. RODRIGUEZ-TAJES S, POCURULL A, CASTILLO J, CASANOVA G, VEGA L, LENS S, et al. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. J Hepatol, 2020, 73: 1360-1367.
23. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol, 2020, 73: 1170-1218.
24. FERNANDEZ CARRILLO C, LENS S, LLOP E, PASCASIO JM, CRESPO J, ARENAS J, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. Hepatol, 2017, 65: 1810-1822.
25. PEARLMAN BL. Direct-acting antiviral therapy for patients with chronic hepatitis C infection and decompensated cirrhosis. Dig Dis Sci, 2024, 69: 1551-1561.
26.BELLI LS, DUVOUX C, BERENGUER M, BERG T, COILLY A, COLLE I, et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J. Hepatol, 2017, 67: 585-602.
27.PAWLOTSKY JM, NERGO F, AGHEMO A, BERENGUER M, DALGARD O, DUSHEIKO G, et al. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol, 2020, 73: 1170-1218.
28.YE F, ZHAI M, LONG J, GONG Y, REN C, ZHANG D, et al. The burden of liver cirrhosis in mortality: Results from the global burden of disease study. Front Public Health, 2022, 10: 909455.
29.WEWERS ME, LOWE NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Research in Nursing and Health, 1990, 13: 227-236.
30.FLISIAK R, POGORZELSKA J, BERAK H, HORBAN A, ORŁOWSKA I, SIMON K, et al. Efficacy of HCV treatment in Poland at the turn of the interferon era — the EpiTer study. Clin Exp Hepatol, 2016, 2: 138-143.
31.MACH TH, CIEŚLA A, WARUNEK W, JANAS-SKULINA U, CIBOR D, OWCZAREK D, et al. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Pol Arch Med Wewn, 2011, 121: 434-439.
32.PABJAN P, BRZDĘK M, CHRAPEK M, DZIEDZIC K, STĘIEŃ PM, PALUCH K. et al. Genotype-specific versus pangenotypic regimens in patients infected with hepatitis C virus genotype 1b in real-world settings. Pol Arch Intern Med, 2021, 131: 16094.
33.KHULLAR V, FIRPI RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol, 2015, 7: 1843-1855.
34.ROUDOT-THORAVAL F. Epidemiology of hepatitis C virus infection. Clin. Res. Hepatol. Gastroenterol, 2021, 45: 101596.
35.ZOUGHLAMI A, SERERO J, CONGLY S, ZHAO I, ZHU J, RAMJI A, et al. Diagnosis of esophageal varices by liver stiffness and serum biomarkers in virus-related compensated advanced chronic liver disease. Can Liver J, 2023, 6: 332-346.
36.D′AMICO G, De FRANCHIS R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology, 2003, 38: 599-612.
37.GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, BOSCH J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 2017, 65: 310-335.
38.MEN C, ZHANG G. Endoscopic ultrasonography predicts early esophageal variceal bleeding in liver cirrhosis: A case report. Medicine (Baltimore), 2017, 96: e6749.
39.SHETH SG, FLAMM S, GORDON FD, CHOPRA S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol, 1998, 93: 44-48.
40.ANDERSON FH, ZENG L, ROCK NR, YOSHIDA EMY. An assessment of the clinical utility of serum ALT and AST in chronic hepatitis C. Hepatology Research, 2000, 18: 63-71.
41. NORTHUP PG, LISMAN T, ROBERTS LN. Treatment of bleeding in patients with liver disease. J Thromb Hemost, 2021, 19: 1644-1652.
42.VILL V, RODRIGUES SG, BERZIGOTTI A. Current treatment options of refractory ascites in liver cirrhosis – A systematic review and meta-analysis. Digestive and Liver Disease, 2022, 54: 1007-1014.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 L. Sierpińska, M. Januszek

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 83
Number of citations: 0